Pro-Dex, Inc. — Form 10-K Summary
Business context and reporting period
This filing covers the fiscal year ended June 30, 2019, compared with the fiscal year ended June 30, 2018; it is not a standalone fourth-quarter report. Pro-Dex designs and manufactures powered surgical instruments, primarily for orthopedic and craniomaxillofacial applications, and also sells rotary air motors. Medical devices generated 90% of FY2019 sales. The company sold its Fineline molding business in May 2018 and reports one operating segment.
Financial performance and liquidity
| Metric | FY2019 | FY2018 |
|---|---|---|
| Net sales | $27.172 million | $22.465 million |
| Gross profit / margin | $9.780 million / 36% | $7.943 million / 35% |
| Operating income / margin | $4.998 million / 18% | $2.392 million / 11% |
| Net income / diluted EPS | $4.148 million / $0.97 | $1.621 million / $0.37 |
| Cash from operations | $3.326 million | $3.096 million |
- Sales rose 21%, led by medical-device sales, which increased $4.3 million. Sales to the largest customer grew to $17.1 million from $12.5 million.
- Cash and cash equivalents were $7.742 million and working capital was $17.513 million at year-end, compared with $5.188 million and $13.818 million, respectively, in 2018.
- Long-term debt under the Minnesota Bank & Trust term loan was approximately $4.6 million at year-end. The $5 million term loan bears fixed interest of 5.53% and matures in 2025. The separate $2 million revolving facility had not been drawn; it was due to mature in September 2019, and management said it anticipated renewal.
- Investing cash outflow was $1.222 million, including $1.387 million of capital expenditures. Financing cash inflow was $450,000, reflecting the term loan and share repurchases.
- Marketable equity securities had a year-end fair value of $3.231 million and unrealized losses of $549,000. Net income included a $356,000 gain on sale of investments.
Changes versus the prior year
- Operating income more than doubled, with higher sales and gross margin and no repeat of FY2018’s $1.029 million asset impairment charge. FY2018 impairment included an $800,000 write-down of the Monogram investment and $229,000 related to Fineline.
- Repairs revenue increased 189% to $1.137 million, largely for products sold to the largest customer. Dental and component sales fell 31% as the company discontinued its dental product line; Fineline and ESD-related revenue also largely disappeared.
- Inventory increased to $6.239 million from $4.393 million, and accounts receivable rose to $4.100 million from $2.955 million, reflecting higher expected sales and customer demand.
- Net debt increased following the new term loan, while cash also grew. The company repurchased 322,068 shares for approximately $4.0 million, versus 33,026 shares for $220,000 in FY2018.
Outlook, risks, and unusual items
- Backlog was $17.7 million at June 30, 2019, up from $12.3 million a year earlier; management expected all of it to ship in FY2020. Backlog is firm acknowledged orders, does not include all expected contract revenue, and bookings can vary.
- Management stated that available cash, receivables, and expected operating cash flow should fund the business for at least 12 months. It noted possible future needs for debt or equity capital, particularly to fund working capital and manufacturing equipment.
- Development priorities include a thoracic driver, arthroscopic products, and a customer-specific CMF driver. The filing lists estimated launch dates and potential annual revenue for projects, but these are project estimates, not formal company guidance. Management anticipates increased sales to an existing customer in FY2020 from a new thoracic driver.
- Customer concentration is a major risk: the largest customer represented 63% of FY2019 sales and had a supply agreement for surgical handpieces through calendar 2021. The top 20 customers represented 98% of sales. Customers may also alter or cancel purchase orders.
- Other material risks include competition and product-development execution, supplier concentration, medical-device regulation and warranty exposure. The company recorded a $63,000 accrual related to a previously announced recall of legacy batteries. The Affordable Care Act’s 2.3% medical-device excise tax was suspended through December 31, 2019, but could affect margins if reinstated.
- The $1.15 million hotel-loan participation was repaid in full during FY2019. The company also disclosed related-party connections involving some investment decisions and securities holdings. A thinly traded public-company investment was classified as long-term and independently valued.
- Adoption of lease accounting on July 1, 2019 was expected to increase reported assets and liabilities by approximately $3.3 million. The company reported effective disclosure controls and internal control over financial reporting; the auditor did not provide an ICFR attestation.
Important facts for investors to verify
- Whether the largest customer sustains demand and fulfills the supply agreement, and whether Pro-Dex can diversify its customer base.
- Whether the $17.7 million backlog converts to FY2020 shipments and cash collections on schedule, given elevated inventory and receivables.
- The status and renewal terms of the revolving credit facility, compliance with debt covenants, and the company’s ability to fund operations and capital needs.
- Actual launch timing, customer adoption, and revenue from development programs versus management’s project estimates.
- The valuation and liquidity of marketable securities, particularly the thinly traded investment, and any related-party governance considerations.